An evidence-based review of the potential role of icatibant in the treatment of acute attacks in hereditary angioedema type i and II

Core Evidence

Volumn 7, Issue , 2012, Pages 105-114

  Floccard, Bernard ^a   Hautin, Etienne ^a   Bouillet, Laurence ^b   Coppere, Brigitte ^a   Allaouchiche, Bernard ^a  

^a HOSPICES CIVILS DE LYON   (France)

^b GRENOBLE UNIVERSITY HOSPITAL   (France)

Author keywords

Acute attacks; Hereditary angioedema; Icatibant; Self administration

Indexed keywords

ANALGESIC AGENT; ANTIEMETIC AGENT; CETOR; COMPLEMENT COMPONENT C1S INHIBITOR; ECALLANTIDE; ICATIBANT; NARCOTIC AGENT; PLACEBO; TRANEXAMIC ACID; UNCLASSIFIED DRUG;

ANGIONEUROTIC EDEMA; BREAST FEEDING; DRUG EFFICACY; DRUG SAFETY; DRUG SELF ADMINISTRATION; EVIDENCE BASED MEDICINE; HEART INFARCTION; HUMAN; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE SWELLING; MEDLINE; NONHUMAN; OPTIMAL DRUG DOSE; PATHOPHYSIOLOGY; PEER REVIEW; PHARMACODYNAMICS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PREGNANCY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; REVIEW; SINGLE DRUG DOSE; VALIDITY; VISUAL ANALOG SCALE;

EID: 84873206589     PISSN: 15551741     EISSN: None     Source Type: Journal    
DOI: 10.2147/CE.S24743     Document Type: Review

References (55)

1. Zuraw BL. Clinical practice. Hereditary angioedema. N Engl J Med. 2008;359(10):1027-1036.
2. Longhurst H, Cicardi M. Hereditary angioedema. Lancet. 2012; 379(9814):474-481.
3. Agostoni A, Aygoren-Pursun E, Binkley KE, et al. Hereditary and acquired angioedema: problems and progress: proceedings of the third C1 esterase inhibitor deficiency workshop and beyond. J Allergy Clin Immunol. 2004;114(Suppl 3):S51-131.
4. Bork K, Barnstedt SE. Laryngeal edema and death from asphyxiation after tooth extraction in four patients with hereditary angioedema. J Am Dent Assoc. 2003;134(8):1088-1094. (Pubitemid 38175476)
5. Bork K, Hardt J, Schicketanz KH, Ressel N. Clinical studies of sudden upper airway obstruction in patients with hereditary angioedema due to C1 esterase inhibitor deficiency. Arch Intern Med. 2003; 163(10):1229-1235. (Pubitemid 36613077)
6. Bork K, Hardt J, Staubach-Renz P, Witzke G. Risk of laryngeal edema and facial swellings after tooth extraction in patients with hereditary angioedema with and without prophylaxis with C1 inhibitor concentrate: a retrospective study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2011;112(1):58-64.
7. Bork K, Siedlecki K, Bosch S, Schopf RE, Kreuz W. Asphyxiation by laryngeal edema in patients with hereditary angioedema. Mayo Clinic Proc. 2000;75(4):349-354. (Pubitemid 30187107)
8. Davis AE 3rd. The pathophysiology of hereditary angioedema. Clin Immunol. 2005;114(1):3-9.
9. Maurer M, Bader M, Bas M, et al. New topics in bradykinin research. Allergy. 2011;66(11):1397-1406.
10. Bas M, Adams V, Suvorava T, Niehues T, Hoffmann TK, Kojda G. Nonallergic angioedema: role of bradykinin. Allergy. 2007;62(8):842-856. (Pubitemid 47037860)
11. Kaplan A. Bradykinin and the pathogenesis of hereditary angioedema. World Allergy Organiz J. 2011;4(4):73-75.
12. Bossi F, Fischetti F, Regoli D, et al. Novel pathogenic mechanism and therapeutic approaches to angioedema associated with C1 inhibitor deficiency. J Allergy Clin Immunol. 2009;124(6):1303-1310. e4.
13. Bowen T, Brosz J, Brosz K, Hebert J, Ritchie B. Management of hereditary angioedema: 2010 Canadian approach. Allergy Asthma Clin Immunol. 2010;6(1):20.
14. Bowen T, Cicardi M, Farkas H, et al. 2010 International consensus algorithm for the diagnosis, therapy and management of hereditary angioedema. Allergy Asthma Clin Immunol. 2010;6(1):24.
15. Bowen T. Hereditary angioedema: beyond international consensus - circa December 2010 - The Canadian Society of Allergy and Clinical Immunology Dr David McCourtie Lecture. Allergy Asthma Clin Immunol. 2011;7(1):1.
16. Cicardi M, Bork K, Caballero T, et al. Evidence-based recommendations for the therapeutic management of angioedema owing to hereditary C1 inhibitor deficiency: consensus report of an International Working Group. Allergy. 2011;67(2):147-157.
17. Caballero T, Baeza ML, Cabanas R, et al. Consensus statement on the diagnosis, management, and treatment of angioedema mediated by bradykinin. Part I. Classification, epidemiology, pathophysiology, genetics, clinical symptoms, and diagnosis. J Investig Allergol Clin Immunol. 2011;21(5):333-347; quiz follow 47.
18. Caballero T, Baeza ML, Cabanas R, et al. Consensus statement on the diagnosis, management, and treatment of angioedema mediated by bradykinin. Part II. Treatment, follow-up, and special situations. J Investig Allergol Clin Immunol. 2011;21(6):422-441; quiz 42-43.
19. Cicardi M, Banerji A, Bracho F, et al. Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema. N Engl J Med. 2010;363(6):532-541.
20. Craig TJ, Bewtra AK, Bahna SL, et al. C1 esterase inhibitor concentrate in 1085 Hereditary Angioedema attacks - final results of the IMPACT2 study. Allergy. 2011;66(12):1604-1611.
21. Craig TJ, Levy RJ, Wasserman RL, et al. Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacks. J Allergy Clin Immunol. 2009;124(4):801-808.
22. Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Evaluation Agency. CHMP assessment report for Firazyr. 11-7-2008. [website on the Internet]. Available from: http://www.ema.europa.eu/docs/en-Gb/ document-library/EPAR-Public-assessment-report/human/000899/WC500022970.pdf. Accessed January 25, 2012.
23. US Food and Drug Administration. Advisory Committee Meeting Briefing Package. Firazyr® (icatibant). 23-06-2011. [website on the Internet]. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/ CommitteesMeetingMaterials/Drugs/Pulmonary-AllergyDrugsAdvisoryCommittee/ UCM260022.pdf. Accessed January 25, 2012.
24. Fox RH, Goldsmith R, Kidd DJ, Lewis GP. Bradykinin as a vasodilator in man. J Physiol. 1961;157:589-602.
25. Hock FJ, Wirth K, Albus U, et al. Hoe 140 a new potent and long acting bradykinin-antagonist: in vitro studies. Br J Pharmacol. 1991;102(3):769-773.
26. Feletou M, Martin CA, Molimard M, et al. In vitro effects of HOE 140 in human bronchial and vascular tissue. Eur J Pharmacol. 1995;274(1-3):57-64.
27. Deeks ED. Icatibant. Drugs. 2010;70(1):73-81.
28. Longhurst HJ, Farkas H, Craig T, et al. HAE international home therapy consensus document. Allergy Asthma Clin Immunol. 2010;6(1):22.
29. Lumry WR, Li HH, Levy RJ, et al. Randomized placebo-controlled trial of the bradykinin B receptor antagonist icatibant for the treatment of acute attacks of hereditary angioedema: the FAST-3 trial. Ann Allergy Asthma Immunol. 2011;107(6):529-537.
30. Clark W, Mucklow J. Gathering and weighing the evidence. In: Panton R, Chapman S, editors. Medicines Management. London: BMJ Books and Pharmaceutical Press; 1998.
31. Bork K, Frank J, Grundt B, Schlattmann P, Nussberger J, Kreuz W. Treatment of acute edema attacks in hereditary angioedema with a bradykinin receptor-2 antagonist (Icatibant). J Allergy Clin Immunol. 2007;119(6):1497- 1503. (Pubitemid 46855846)
32. Bas M, Bier H, Greve J, Kojda G, Hoffmann TK. Novel pharmacotherapy of acute hereditary angioedema with bradykinin B2-receptor antagonist icatibant. Allergy. 2006;61(12):1490-1492. (Pubitemid 44665321)
33. Krause K, Metz M, Zuberbier T, Maurer M, Magerl M. Successful treatment of hereditary angioedema with bradykinin B2-receptor antagonist icatibant. J Dtsch Dermatol Ges. 2010;8(4):272-274.
34. Bouillet L, Boccon-Gibod I, Dumestre-Perard C, Cesbron JY, Massot C. Efficacy of icatibant treatment in patients with hereditary angioedema type I resistant to treatment with C1 inhibitor concentrate. Br J Dermatol. 2011;164(6):1406-1407.
35. Firinu D, Barca MP, Serusi L, et al. Switch to icatibant in a patient affected by hereditary angioedema with high disease activity: a case report. Int J Immunopathol Pharmacol. 2012;25(1):269-273.
36. Farkas H, Csuka D, Zotter Z, et al. Home treatment of hereditary angioedema with icatibant administered by health care professionals. J Allergy Clin Immunol. 2012;129(3):851-852. e2.
37. Christiansen SC, Zuraw BL. Hereditary angioedema: management of laryngeal attacks. Am J Rhinol Allergy. 2011;25(6):379-382.
38. Longhurst HJ. Management of acute attacks of hereditary angioedema: potential role of icatibant. Vasc Health Risk Manag. 2010;6:795-802.
39. Greve J, Hoffmann TK, Schuler P, Lang S, Chaker A, Bas M. Successful long-term treatment with the bradykinin B2 receptor antagonist icatibant in a patient with hereditary angioedema. Int J Dermatol. 2011;50(10):1294-1295.
40. Drake D. Towards evidence-based emergency medicine: best BETs from the Manchester Royal Infirmary. Management of adult patients with icatibant in hereditary angioedema. Emerg Med J. 2011;28(8):720-721.
41. Bouillet L. Icatibant in hereditary angioedema: news and challenges. Expert Rev Clin Immunol. 2011;7(3):267-272.
42. Bork K, Meng G, Staubach P, Hardt J. Treatment with C1 inhibitor concentrate in abdominal pain attacks of patients with hereditary angioedema. Transfusion. 2005;45(11):1774-1784. (Pubitemid 43923905)
43. Toscani M, Riedl M. Meeting the challenges and burdens associated with hereditary angioedema. Manag Care. 2011;20(9):44-51.
44. Wilson DA, Bork K, Shea EP, Rentz AM, Blaustein MB, Pullman WE. Economic costs associated with acute attacks and long-term management of hereditary angioedema. Ann Allergy Asthma Immunol. 2010; 104(4):314-320.
45. Aygoren-Pursun E, Martinez-Saguer I, Rusicke E, Klingebiel T, Kreuz W. On demand treatment and home therapy of hereditary angioedema in Germany - the Frankfurt experience. Allergy Asthma Clin Immunol. 2010;6(1):21.
46. Lumry WR, Castaldo AJ, Vernon MK, Blaustein MB, Wilson DA, Horn PT. The humanistic burden of hereditary angioedema: impact on health-related quality of life, productivity, and depression. Allergy Asthma Proc. 2010;31(5):407-414.
47. Bright P, Dempster J, Longhurst H. Successful treatment of acquired C1 inhibitor deficiency with icatibant. Clin Exp Dermatol. 2010;35(5):553-554.
48. Bouillet L. Hereditary angioedema in women. Allergy Asthma Clin Immunol. 2010;6(1):17.
49. Bouillet L, Boccon-Gibod I, Ponard D, et al. Bradykinin receptor 2 antagonist (icatibant) for hereditary angioedema type III attacks. Ann Allergy Asthma Immunol. 2009;103(5):448.
50. Weller K, Magerl M, Maurer M. Successful treatment of an acute attack of acquired angioedema with the bradykinin-B2-receptor antagonist icatibant. J Eur Acad Dermatol Venereol. 2011;25(1):119-120.
51. Gallitelli M, Alzetta M. Icatibant: a novel approach to the treatment of angioedema related to the use of angiotensin-converting enzyme inhibitors. Am J Emerg Med. November 17, 2011. [In press].
52. Guichon C, Floccard B, Coppere B, et al. One hypovolaemic shock*two kinin pathway abnormalities. Intensive Care Med. 2011;37(7):1227-1228.
53. Bas M, Greve J, Stelter K, et al. Therapeutic efficacy of icatibant in angioedema induced by angiotensin-converting enzyme inhibitors: a case series. Ann Emerg Med. 2010;56(3):278-282.
54. Blankart CR, Stargardt T, Schreyogg J. Availability of and access to orphan drugs: an international comparison of pharmaceutical treatments for pulmonary arterial hypertension, Fabry disease, hereditary angioedema and chronic myeloid leukemia. Pharmacoeconomics. 2011;29(1):63-82.
55. Simoens S. Pricing and reimbursement of orphan drugs: the need for more transparency. Orphanet J Rare Dis. 2011;6:42.